Corticosteroid-regulated genes in rat kidney: Mining time series array data

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 5 52-5, 2005, Pages

  Almon, Richard R ^a   Lai, William ^a   DuBois, Debra C ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Data mining; Evolutionary conservation; Gene arrays; Glucocorticoids; Pharmacogenomics

Indexed keywords

CORTICOSTEROID; DNA; METHYLPREDNISOLONE; RNA;

5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; DATA ANALYSIS; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC CONSERVATION; HORMONAL REGULATION; KIDNEY; MALE; MATHEMATICAL MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RNA PROBE; TECHNIQUE;

ANIMALS; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; KIDNEY; MALE; METHYLPREDNISOLONE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 27144458368     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00196.2005     Document Type: Article

References (60)

1. Almon R, DuBois D, Jin J, and Jusko W. Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. AAPS J. 7: E156-E194, 2005.
2. Almon R, DuBois DC, Pearson K, Stephan D, and Jusko WJ. Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver. Funct Integr Genomics 3: 171-179, 2003.
3. Almon RR, Chen J, Snyder G, DuBois D, Jusko W, and Hoffman E. In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR). Pharmacogenomics 4: 791-799, 2003.
4. Almon RR, DuBois DC, Piel W, and Jusko WJ. The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series. Pharmacogenomics 5: 525-552, 2004.
5. Althus M and Nagamine Y. Protein synthesis inhibition stabalizes urokinase-type plasminogen activator mRNA. J Biol Chem 266: 21190-21196, 1991.
6. Baxter J. Advances in glucocorticoid therapy. Adv Intern Med 317-349, 2000.
7. Beato M, Chalepakis G, Schauer M, and Slater E. DNA regulatory elements for steroid hormones. J Steroid Biochem 32: 737-748, 1989.
8. Bialis M and Routledge P. Adverse effects of corticosteroids. Adverse Drug React Toxicol Rev 17: 227-235, 1998.
9. Bosse F, Hasse B, Pippirs U, Greiner-Petter K, and Muller H. Proteolipid plasmolipin: localization in polarized cells, regulated expression, and lipid raft association in CNS and PNS myelin. J Neurochem 86: 508-518, 2003.
10. Burns-Kurtis CL, Olzinski AR, Needle S, Fox JH, Capper EA, Kelly FM, McQueney MS, and Romanic AM. Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit. Cardiovasc Res 62: 610-620, 2004.
11. Chen J, Zhao P, Massaro D, Clerch L, Almon RR, DuBois DC, Jusko WJ, and Hoffman E. The PEPR GeneChip Data Warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res 32: 578-581, 2004.
12. Contente S, Csiszar K, Kenyon K, and Friedman R. Structure of the mouse lysyl oxidase gene. Genomics 16: 395-400, 1993.
13. Dammeier J, Beer HD, Brauchte M, and Werner S. Dexamethasone is a novel potent inducer of connective tissue growth factor expression. Implications for glucocorticoid therapy. J Biol Chem 273: 18185-18190, 1998.
14. di Patti MC, Persichini T, Mazzone V, Polticelli F, Colasanti M, and Musci G. Interleukin-1beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferroportin-1 synthesis. Neurosci Lett 363: 182-186, 2004.
15. Edwards C, Stewart P, Burt D, Brett L, McIntyre M, Sutanto W, deKloet E, and Monder C. Localization of 11B-hydroxysteroid dehydrogenase-tissue specific promotor of the mineralocorticoid receptor. Lancet: 986-989, 1988.
16. Eisen MB, Spellman PT, Brown PO, and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
17. Favre CJ, Mancuso M, Maas K, McLean JW, Baluk P, and McDonald DM. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart Circ Physiol 285: H1917-H1938, 2003.
18. Frauman A. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React Toxicol Rev 15: 203-206, 1996.
19. Funder J, Pearce P, Smith R, and Smith A. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585, 1988.
20. Garcia-Mata R and Sztul E. The membrane-tethering protein p115 interacts with GBF1, an ARF guanine-nucletide-exchange factor. EMBO Reports 4: 320-325, 2003.
21. Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL, Grotendorst G, and Trojanowska M. TGF-β and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 283: F707-F716, 2002.
22. Hardison R. Conserved noncoding sequences are reliable guides to regulatory elements. Trends Genet 26: 225-228, 2000.
23. Henderson B and Kefford R. Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 mammary carcinoma cells. Br J Cancer 67: 99-101, 1993.
24. Hsu SC, Hazuka CD, Foletti DL, and Scheller RH. Targeting vesicles to specific sites on the plasma membrane: the role of the sec6/8 complex. Trends Cell Biol 9: 150-153, 1999.
25. Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, Nishida T, Takigawa M, Ueno M, Nakamura T, and Suzuki H. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 17: 268-270, 2003.
26. Jin JY, Almon RR, DuBois DC, and Jusko WJ. Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther 307: 93-109, 2003.
27. Jusko WJ, Jin JY, DuBois DC, and Almon RR. Pharmacodynamics and pharmacogenomics of corticosteroids: microarray studies. In: Advanced Methods of Pharmacokinetic and Pharmacodynamics Systems Analysis, edited by D'Argenio D. Boston, MA: Kluwer Academic, 2004.
28. Kennedy B, Elayan H, and Ziegler MG. Glucocorticoid hypertension and nonadrenal phenylethanolamine N-methyltransferase. Hypertension 21: 415-419, 1993.
29. Lang C, Nystrom G, and Frost R. Burn-induced changes in IGF-1 and IGF-binding proteins are partially glucocorticoid dependent. Am J Physiol Regul Integr Comp Physiol 282: R207-R215, 2002.
30. Lewin B. Genes V. New York: Oxford Univ. Press, 1994.
31. Lewin B. Genes VIII. Pearson-Prentice Hall, 2004.
32. Locsey L, Asztalos L, Kineses Z, Gyorfi F, and Berczi C. Dyslipidaemia and hyperlipidaemia following renal transplantation. Int Urol Nephrol 28: 419-430, 1996.
33. Matsuda K and Fukushima C. Identification of glucocorticoid and cyclic AMP responsive elements of the rat serine dehydratase gene: difference in responses of the transfected and chromosomal genes. Biochem Biophys Res Commun 176: 385-391, 1991.
34. McKay LI, DuBois DC, Sun YN, Almon RR, and Jusko WJ. Corticosteroid effects in skeletal muscle: gene induction/receptor autoregulation. Muscle Nerve 20: 1318-1320, 1997.
35. Mok H, Jelinek J, Pai S, Cattanach BM, Prchal JT, Youssoufian H, and Schumacher A. Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. Development 131: 1859-1868, 2004.
36. Moses A, Chiang D, Pollard D, Iyer V, and Eisen M. MONKEY: identifying conserved transcription-factor binding sites in multiple alignments using a binding site-specific evolutionary model. Genome Biol 5: R98, 2004.
37. Mukai K, Mitani F, Nagasawa H, Suzuki R, Suzuki T, Suematsu M, and Ishimura Y. An inverse correlation between expression of a preprocathepsin B-related protein with cysteine-rich sequences and steroid 11beta-hydroxylase in adrenocortical cells. J Biol Chem 278: 17084-17092, 2003.
38. Mune T, Rogerson F, Nikkila J, Agarwal A, and White P. Human hypertension caused by mutations in the kidney isozyme of 11B-hydroxysteroid dehydrogenase. Nat Genet 10: 394-399, 1995.
39. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55: 603-613, 2000.
40. Nichols AI, Boudinot FD, and Jusko WJ. Second generation model for prednisolone pharmacodynamics in the rat. J Pharmacokinet Biopharm 17: 209-227, 1989.
41. Pearson D, Altus M, Horiechi A, and Nagamine Y. Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells. Biochem Biophys Res Commun 143: 329-336, 1987.
42. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, Lombardi DM, Schwartz SM, Bennett WM, Alpers CE, Sage EH, Johnson RJ, and Couser WG. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 50: 1978-1989, 1978.
43. Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, and Jusko WJ. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn 29: 1-24, 2002.
44. Reynolds RM and Walker BR. Human insulin resistance: the role of glucocorticoids. Diabet Obes Metab 5: 5-12, 2003.
45. Rizkalla B, Forbes JM, Cooper ME, and Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 14: 3061-3071, 2003.
46. Sanai T, Sobka T, Johnson T, el-Essawy M, Muchaneta-Kubara EC, Ben Gharbia O, el Oldroyd S, and Nahas AM. Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy. Diabetologia 43: 91-100, 2000.
47. Sasaki CY, Lin H, and Passaniti A. Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells. J Cell Physiol 181: 1-13, 1999.
48. Schaaf M and Cidlowski J. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83: 37-48, 2003.
49. Schacke H, Docke WD, and Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43, 2002.
50. Schimmer B and Parker K. Adrenocorticotrophic hormones, adrenocortical steroids and their synthetic analogs, inhibitors of synthesis and actions of adrenocortical hormones. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, edited by Hardman J, Limbird L, Molinoff B, Ruddon R, and Goodman-Gilman A. New York: McGraw Hill, 1996, p. 1459-1486.
51. Stewart P, Corrie J, Schackleton C, and Edwards C. Syndrome of apparent mineralocorticoid excess: a defect in the cortisol-cortisone shuttle. J Clin Invest 82: 340-349, 1988.
52. Sun YN, DuBois DC, Almon RR, and Jusko WJ. Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm 26: 289-317, 1998.
53. Sun YN, DuBois DC, Almon RR, Pyszczynski NA, and Jusko WJ. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm 26: 619-648, 1998.
54. Sun YN, McKay LI, DuBois DC, Jusko WJ, and Almon RR. Pharmacokinetic/ Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism. J Pharmacol Exp Ther 288: 720-728, 1999.
55. Tankiewicz A, Pawlak D, Topczewska-Bruns J, and Buczko W. Kidney and liver kynurenine pathway enzymes in chronic renal failure. Adv Exp Med Biol 527: 409-414, 2003.
56. UM, Shen L, Oshida T, Miyauchi J, Yamada M, and Miyashita T. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 18: 1850-1856, 2004.
57. Vannucci S and Simpson I. Developmental switch in brain nutrient transporter expression in the rat. Am J Physiol Endocrinol Metab 285: E1127-E1134, 2003.
58. Xu ZX, Sun YN, DuBois DC, Almon RR, and Jusko WJ. Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm 23: 163-181, 1995.
59. Yeagley D, Guo S, Unterman T, and Quinn P. Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-I and phosphoenolpyruvate carboxykinase transcription. J Biol Chem 36: 33705-33710, 2001.
60. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, and Nakao K. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis. Am J Kidney Dis 38: S134-S138, 2001.